Pharmafile Logo

infill healthcare communications

- PMLiVE

New Webinar: 2026 Engagement Strategies For Modern Pharma

Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!

Impetus Digital

- PMLiVE

Havas Life London unveils AI awareness campaign

The campaign highlights the dangers of AI misinformation in rare disease

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

Healthcare setting

Clinical research in 2026: The trends shaping tomorrow

Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

AstraZeneca reports positive results from rare disease trial

HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

- PMLiVE

Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

Uniphar

Epilepsy meds app silver award at PMi Awards

Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App

Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.

Genetic Digital

Streamlining European expansion for cell and gene therapies

Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

Uniphar

- PMLiVE

Current CGT landscape and future outlook  

What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

Uniphar

- PMLiVE

Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

Uniphar

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links